Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | July 10, 2023 | July 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Faeth Therapeutics, Inc.
Report date July 10, 2023 · Filed July 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,932 |
Reported balance
After 2023-07-10 transaction · row 1
1 source rowRow 1 · 2023-07-10 · Grant · Acquired 4,466 · Balance 8,932 F1: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2033-07-09 | Direct | 14,550 |
Reported balance
After 2023-07-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-10 · Grant · Acquired 14,550 · Balance 14,550 F2: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
F2: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Orion Biotech Opportunities Corp.
Report date May 17, 2023 · Filed May 18, 2023
Section 16 reporting ended · disclosed 2023-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-17 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2023 Filed Jul 12, 2023 21:00 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042101 · doc4.xml · derivative · entry 2 Broder Samuel · CIK 0001340543 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2033-07-09 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 21:00 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 4,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042101 · doc4.xml · nonDerivative · entry 1 Broder Samuel · CIK 0001340543 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,932 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 17, 2023 Filed May 18, 2023 16:05 UTC | Orion Biotech Opportunities Corp. ORIA · Entity 113330 | Disposition to issuerClass B ordinary shares · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-041170 · ownership.xml · derivative · entry 1 Broder Samuel · CIK 0001340543 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. F1 · derivative.exercise_date: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. F1 · derivative.expiration_date: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001209191-22-036666 · doc4.xml · derivative · entry 2 Broder Samuel · CIK 0001340543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2032-06-09 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 4,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036666 · doc4.xml · nonDerivative · entry 1 Broder Samuel · CIK 0001340543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,466 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:35 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008074 · doc4.xml · derivative · entry 1 Broder Samuel · CIK 0001340543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2031-02-02 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the options granted shall vest and become exercisable each month following February 3, 2021, the Vesting Commencement Date, over three years such that the options shall be 100% vested on the third anniversary of the Vesting Commencement Date, subject to the grantee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.